Program
daridorexant
Also written as “Daridorexant”, “ACT-541468” and “Daridorexant 25 mg”.
Its studies are mostly in Sleep Initiation and Maintenance Disorders · Sleep Apnea, Obstructive · Renal Insufficiency · Pulmonary Disease, Chronic Obstructive, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Idorsia Pharmaceuticals | 311 open or running | phase 4since Oct 25, 2022 | Aug 14, 2015 | Nov 22, 2027phase 3 · NCT07843329 |
| Simcere Pharmaceutical Group | 20 open or running | phase 3since Aug 20, 2023 | Aug 20, 2023 | none ahead |
| Nxera Pharma Korea | 10 open or running | phase 3since Jun 11, 2025 | Jun 11, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 17 studies since Aug 14, 2015.
- Mar 21, 20192 phase 1 studies in HealthyIdorsia Pharmaceuticals · NCT03907215, NCT03892902
- Jul 16, 2019Phase 1 study in Renal InsufficiencyIdorsia Pharmaceuticals · NCT04024332 · 16 enrolled · Germany
- Jan 30, 2020Phase 1 study in HealthyIdorsia Pharmaceuticals · NCT04250506 · 36 enrolled · Czechia
- May 12, 2020Phase 1 study in HealthyIdorsia Pharmaceuticals · NCT04390334 · 24 enrolled · Germany
- Jun 14, 2022Phase 2 study in Sleep Initiation and Maintenance DisordersIdorsia Pharmaceuticals · NCT05423717 · 166 enrolled · United States, Bulgaria, Germany and more
- Jul 11, 20223 phase 1 studiesIdorsia Pharmaceuticals · NCT05458193, NCT05480488, NCT05480475
- Oct 25, 2022Phase 4 study in Sleep Initiation and Maintenance DisordersIdorsia Pharmaceuticals · NCT05597020 · 60 enrolled · United States, Germany, Spain
- Nov 8, 2022Phase 1 study in HealthyIdorsia Pharmaceuticals · NCT05632393 · 10 enrolled · United States
- Jan 5, 2023Phase 1 study in HealthyIdorsia Pharmaceuticals · NCT05702177 · 36 enrolled · Netherlands
- May 17, 2023Phase 1 study in HealthyIdorsia Pharmaceuticals · NCT05877222 · 38 enrolled · United States
- Aug 20, 2023Simcere Pharmaceutical Group's first study: phase 3 study in Sleep Initiation and Maintenance DisordersNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT06010693 · 206 enrolled · China
- Feb 17, 2024Phase 1 study in Healthy VolunteerSimcere Pharmaceutical Group · NCT06326723 · 32 enrolled · China
- Jun 11, 2025Nxera Pharma Korea's first study: phase 3 study in Sleep Initiation and Maintenance DisordersNew to Nxera Pharma KoreaNxera Pharma Korea · NCT07028697 · 164 enrolled · South Korea
- Sep 21, 2026Phase 3 study in Insomia DisorderIdorsia Pharmaceuticals · NCT07843329 · 344 planned · United States
Ahead
- Nov 22, 2027Primary completion: phase 3 study in Insomia DisorderIdorsia Pharmaceuticals · NCT07843329
TargetBeta
“Orexin receptor antagonist; Orexin receptor 1 antagonist; Orexin receptor 2 antagonist”ChEMBL 37, by rule
Studies
All 34 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07843329Insomia Disorder · United States | 3 | Recruiting | Idorsia Pharmaceuticals | Nov 22, 2027 | 344 |
| NCT07028697Sleep Initiation and Maintenance Disorders · South Korea | 3 | Completed | Nxera Pharma Korea | Sep 23, 2025 | 164 |
| NCT06326723Healthy Volunteer · China | 1 | Completed | Simcere Pharmaceutical Group | Dec 24, 2023 | 32 |
| NCT06010693Sleep Initiation and Maintenance Disorders · China | 3 | Completed | Simcere Pharmaceutical Group | Apr 12, 2024 | 206 |
| NCT05877222Healthy · United States | 1 | Completed | Idorsia Pharmaceuticals | Aug 4, 2023 | 38 |
| NCT05702177Healthy · Netherlands | 1 | Completed | Idorsia Pharmaceuticals | Apr 25, 2023 | 36 |
| NCT05632393Healthy · United States | 1 | Completed | Idorsia Pharmaceuticals | Apr 30, 2023 | 10 |
| NCT05597020Sleep Initiation and Maintenance Disorders · United States, Germany, Spain | 4 | Completed | Idorsia Pharmaceuticals | Apr 12, 2024 | 60 |
| NCT05480488Healthy · Germany | 1 | Completed | Idorsia Pharmaceuticals | Sep 23, 2022 | 18 |
| NCT05480475Healthy · Czechia | 1 | Completed | Idorsia Pharmaceuticals | Sep 17, 2022 | 24 |
| NCT05458193Obstructive Sleep Apnea of Adult · Germany | 1 | Completed | Idorsia Pharmaceuticals | Feb 28, 2023 | 20 |
| NCT05423717Sleep Initiation and Maintenance Disorders · United States, Bulgaria, Germany and more | 2 | Completed | Idorsia Pharmaceuticals | Jan 12, 2026 | 166 |
| NCT04390334Healthy · Germany | 1 | Completed | Idorsia Pharmaceuticals | Jun 26, 2020 | 24 |
| NCT04250506Healthy · Czechia | 1 | Completed | Idorsia Pharmaceuticals | Jul 22, 2020 | 36 |
| NCT04024332Renal Insufficiency · Germany | 1 | Completed | Idorsia Pharmaceuticals | Aug 14, 2020 | 16 |
| NCT03907215Healthy · Germany | 1 | Completed | Idorsia Pharmaceuticals | Jun 26, 2019 | 24 |
| NCT03892902Healthy · Netherlands | 1 | Completed | Idorsia Pharmaceuticals | Oct 10, 2019 | 56 |
| NCT03799978Healthy · Czechia | 1 | Completed | Idorsia Pharmaceuticals | Mar 18, 2019 | 20 |
| NCT03765294Sleep Apnea, Obstructive · Germany | 1 | Completed | Idorsia Pharmaceuticals | Nov 5, 2019 | 28 |
| NCT03713242Hepatic Impairment · Switzerland | 1 | Completed | Idorsia Pharmaceuticals | Feb 27, 2020 | 32 |
| NCT03679884Sleep Initiation and Maintenance Disorders · United States, Belgium, Bulgaria and more | 3 | Completed | Idorsia Pharmaceuticals | Feb 22, 2021 | 804 |
| NCT03657355Healthy Recreational Drug Users · United States, Canada | 1 | Completed | Idorsia Pharmaceuticals | Aug 8, 2019 | 63 |
| NCT03646864Pulmonary Disease, Chronic Obstructive · Germany | 1 | Completed | Idorsia Pharmaceuticals | Sep 19, 2019 | 28 |
| NCT03609775Healthy · Netherlands | 1 | Completed | Idorsia Pharmaceuticals | Oct 9, 2018 | 22 |
| NCT03545191Sleep Initiation and Maintenance Disorders · United States, Australia, Canada and more | 3 | Completed | Idorsia Pharmaceuticals | Jan 25, 2020 | 930 |
| NCT03575104Sleep Initiation and Maintenance Disorders · United States, Belgium, Bulgaria and more | 3 | Completed | Idorsia Pharmaceuticals | Apr 9, 2020 | 924 |
| NCT03339752Healthy Subjects · Czechia | 1 | Completed | Idorsia Pharmaceuticals | Dec 2, 2017 | 20 |
| NCT03101189Healthy Subjects · Netherlands | 1 | Completed | Idorsia Pharmaceuticals | Apr 24, 2017 | 40 |
| NCT03017495Healthy Subjects · Germany | 1 | Completed | Idorsia Pharmaceuticals | Feb 1, 2017 | 20 |
| NCT02919319Healthy Subjects · Netherlands | 1 | Completed | Idorsia Pharmaceuticals | May 1, 2015 | 40 |
| NCT02841709Sleep Initiation and Maintenance Disorders · United States, Germany | 2 | Completed | Idorsia Pharmaceuticals | May 31, 2017 | 58 |
| NCT02839200Sleep Initiation and Maintenance Disorders · United States, Germany, Hungary and more | 2 | Completed | Idorsia Pharmaceuticals | Apr 12, 2017 | 360 |
| NCT02571855Sleep Initiation and Maintenance Disorders · Netherlands | 1 | Completed | Idorsia Pharmaceuticals | Feb 1, 2016 | 85 |
| NCT02526888Healthy Subjects · Germany | 1 | Completed | Idorsia Pharmaceuticals | Nov 1, 2015 | 14 |
How it is read
Names in the registry
- “Daridorexant”, 12 entries
- “ACT-541468”, 12 entries
- “Daridorexant 25 mg”, 5 entries
- “Daridorexant 50 mg”, 4 entries
- “Daridorexant 10 mg”, 3 entries
Conditions, from the studies’ own filings
- Sleep Initiation and Maintenance Disorders, 10 studies
- Sleep Apnea, Obstructive, 2 studies
- Renal Insufficiency, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.